Abstract: Double-stranded ribonucleic acids (dsRNA) of at least 45 bp, preferably of at least 50 bp, which dsRNA include at least one 5?-triphosphate group and further includes at least one chemical modification at a 5? end, at a 3? end and/or at a non-terminal nucleotide. The invention further provides pharmaceutical compositions containing such modified dsRNAs, methods for their production, and to their use in medicine, in particular for immunostimulation and treatment as well as prevention of infectious, autoimmune, degenerative, cancer and tumor diseases.
Abstract: The present invention relates to polyC:poly(G/I) dsRNAs for triggering innate immunity, in particular through toll-like receptor 3 (TLR-3) and, optionally, RIG-I or RIG-I-like receptors (RLRs), as well as compositions and medicaments containing such dsRNAs, methods for their production and their use in medicine, especially immunostimulation and prevention and/or therapy of infections and tumor diseases.
Abstract: The present invention relates to polyC:poly(G/1) dsRNAs for triggering innate immunity, in particular through toll-like receptor 3 (TLR-3) and, optionally, RIG-I or RIG-I—like receptors (RLRs), as well as compositions and medicaments containing such dsRNAs, methods for their production and their use in medicine, especially immunostimulation and prevention and/or therapy of infections and tumor diseases.
Abstract: The present invention relates to a ribonucleic acid (RNA) of double-stranded structure which is capable of triggering Toll-like receptor 3 (TLR-3) and which shows an increased serum stability while simultaneously being unable to be processed by the DICER complex.
Abstract: The present invention relates to a method for exponential amplification of RNA using a primer independent RNA-dependent RNA polymerase (RdRp) wherein reactants are premixed cycle and then transferred into the reaction chamber in which the steps of polymerisation of the complementary strand and separation of the resulting double-stranded RNA occur. The invention also relates to a RNA reactor for carrying out the exponential RNA amplification.
Abstract: The present invention relates to a method for exponential amplification of RNA in vitro by using a thermostable RNA-dependent RNA polymerase (RdRp) of a sapovirus or norovirus.
Abstract: The present invention relates to small-interfering RNA molecules displaying an increased thermodynamic stability at the 3? end of the antisense strand (guide strand) and the 5? end of the sense strand (passenger strand), respectively, in comparison to the base pairing in the seed region. The siRNAs of the present invention display an increased knock-down activity against targeted genes and show an improved resistance to RNAses, in particular serum RNAses. The present invention also relates to a method for the production of the siRNA molecules, a method of target-specific RNA interference making use of the improved siRNA molecules of the invention and pharmaceutical compositions containing the siRNA molecules.
Abstract: The present invention relates to methods for the detection of target RNA sequences and to RNA amplification methods making use of strand displacement techniques employing RNA-dependent RNA polymerases having RNA-oligonucleotide duplex separation activity and being capable of de novo RNA synthesis in the absence of a primer. The present invention further relates to kits for carrying out such methods.
Abstract: The present invention relates to a method for enzymatically synthesizing chemically modified RNA by using RNA-dependent RNA polymerases (RdRp), especially RdRps from viruses of the Caliciviridae family. The method of the present invention is particularly useful for preparing RNA molecules of increased stability especially with respect to RNA degradation, for example for in vivo applications. Further subject matter of the present invention relates to a kit for carrying out the enzymatic synthesis of the chemically modified RNA.